Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in CTD-ILD
NCT04928586Phase 4Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pirfenidone in connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by Qilu Hospital of Shandong University. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on NCT04928586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928586.